CRISPR Genomic Cure Market

CRISPR Genomic Cure Market Overview

According to the latest research by Future Market Insights, the CRISPR Genomic Cure market will undergo a steady growth during 2021-2031.

A gradual increase due to constant research studies being conducted and new verticals of disease treatment being opening can be seen over the mentioned forecast period. The increasing innovations and advancements in genetic engineering will further boost the market

What is Driving Demand for CRISPR Genomic Cure market

The gene-editing tool which was discovered only about 7 years ago, has shown potential to be used in treating wide-range of diseases like cancer, HIV as well as haematological ailments.

n a news article namely,” Quest to use CRISPR against disease gains ground” published in Nature , a 2016 research done in China where CRISPR was used to disable a specific gene which has the ability to shield cancerous cells from the immune system.

Another potential application of this tool is in treating HIV AIDS. The HIV virus sits in the DNA of the immune cells, so, by using CRISPR we can attack it in its inactive form and kill it in its dormant sate.

This will possibly assist in curing the disease. CRISPR’s potential application in gene-editing and opening avenues for curing otherwise incurable diseases is what will make this market achieve a drastic boost by increasing its demand.

CRISPR and COVID19

While many screening tests are in existence which allow rapid detection of COVID19, recent developments in genetic research shows a possible use of gene-editing in fight the virus.

Study done at Stanford University have developed a technique to destroy the base genetic material of the COVID19 virus, thus preventing from affecting the human lungs.

Results of this study came back very promising, reducing 90% of viral load in the human cells. Looking at the current scenario, this virus is mutating continuously and making it difficult to find a definite cure.

Therefore, CRISPR technology seems to be taking its steps in the right direction and giving the CRIPSR Genomic Cure market a bright future.

U.S. and Canada CRISPR Genomic Cure market

US leading the CRISPR Genomic Cure market can be attributed to continuous encouragement for the researchers in doing gene-related research, cancer and rare disease research in the form of strong financial support.

For instance, Leber congenital amaurosis is the most common type of blindness in children which has no treatment as of now.

But, a leading brand in genetic technologies, Editas Medicine Inc., is working on a CRISPR therapy where the respective cells will be edited on a genetic level to restore their function before a child loses the sight completely.

Europe CRISPR Genomic Cure market

Sickle Cell Disease, which is a genetic disease has one of the most common prevalence in Europe and it has affected over 52,000 people, says the data published by Global Blood Therapeutics Inc.

in October 2020. Gene responsible for haemoglobin production which is present in the stem cell of bone marrow get mutated. Pertaining to this researchers are exploring new verticals to improve these numbers.

Take the example of Institute Imagine located in Paris. Scientists there have been successful in extracting and treating the faulty genes from the stem cells and insert them inside the human body again which alleviates the symptoms.

This is a breakthrough in curing the diseases by the means of genomics which will provide the necessary boost to the market.

Who are the key Manufacturing and Supplying Companies in CRISPR Genomic Cure Market

Key players:

• Intellia Therapeutics, Inc.
• Caribou Biosciences, Inc.
• CRISPR Therapeutics
• Editas Medicine, Inc.
• Casebia Therapeutics
• ERS Genomics
• Toolgen Inc.
• Thermo Fisher Scientific, Inc
• Merck KGaA
• Cellectis
• eGenesis
• F.Hoffmann-La Roche Ltd.
• Horizon Discovery Group plc
• GenScript
• Danaher Corporation
• AstraZeneca plc.
• Addgene
• Lonza
• Takara Bio Inc.
• Synthego
• Mammoth Biosciences
• Inscripta, Inc.
• Beam Therapeutics
• Vertex Pharmaceuticals Incorporated
• Hera BioLabs
• OriGene Technologies, Inc.
• Recombinetics, Inc.
• Middle East & Africa

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Key Segments

By Product Type:

• Kits
• Libraries
• Reagents
• Vector design
• Assay Design

By Application:

• Cancer Research and Development
• Alteration of DNA
• Genomic Engineering

By End User:

• Pharmaceutical Companies
• Academics & Government Research Institutes
• Contract Research Organizations (CROs)
• Genetic Research Laboratories

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa